OrbiMed reports 5.8% stake in Forte Biosciences

Forte Biosciences, Inc. Schedule 13G/A shows OrbiMed Advisors LLC beneficially owns 884,230 shares of common stock (4.3%) and OrbiMed Capital LLC beneficially owns 312,725 shares (1.5%).

Rhea-AI Filing Summary

Forte Biosciences, Inc. Schedule 13G/A shows OrbiMed Advisors LLC beneficially owns 884,230 shares of common stock (4.3%) and OrbiMed Capital LLC beneficially owns 312,725 shares (1.5%). The reporting persons state they aggregate 5.8% of the class held on behalf of other persons and that investment and voting power is exercised through a management committee of Carl L. Gordon, Sven H. Borho, and W. Carter Neild.

The filing discloses voting and dispositive power split: OrbiMed Advisors reports shared voting and shared dispositive power over 884,230 shares; OrbiMed Capital reports sole voting and sole dispositive power over 312,725 shares. Signatures are dated 05/15/2026.

Insights

Institutional Ownership Analyst

OrbiMed entities report modest aggregate ownership (5.8%) with split control across entities.

The filings list 884,230 shares (4.3%) under OrbiMed Advisors with shared voting/dispositive power and 312,725 shares (1.5%) under OrbiMed Capital with sole voting/dispositive power. The combined stake is reported as 5.8% held on behalf of other persons.

Who controls votes is defined by a management committee of three named individuals. Subsequent filings would show any changes in aggregate percentage or shifts in voting/dispositive allocations.

Corporate Governance Specialist

Disclosure clarifies attribution and committee-based investment authority rather than individual beneficial ownership.

The report states the management committee (Carl L. Gordon, Sven H. Borho, W. Carter Neild) exercises investment and voting power and that each disclaims beneficial ownership. This indicates the entities, not the individuals, are the reporting owners.

Statements on who holds voting versus dispositive power are explicit; any material change in control or percentage would require amendment filings under applicable rules.

Key Figures

OrbiMed Advisors beneficial ownership: 884,230 shares OrbiMed Advisors percent: 4.3% OrbiMed Capital beneficial ownership: 312,725 shares +3 more

6 metrics

OrbiMed Advisors beneficial ownership 884,230 shares reported in Item 4 as amount beneficially owned

OrbiMed Advisors percent 4.3% percent of class reported in Item 4

OrbiMed Capital beneficial ownership 312,725 shares reported in Item 4 as amount beneficially owned

OrbiMed Capital percent 1.5% percent of class reported in Item 4

Aggregate holding reported 5.8% aggregate percent held on behalf of other persons (Item 6)

Signature date 05/15/2026 date on signature lines

Key Terms

beneficially owned, shared dispositive power, Schedule 13G/A, management committee

4 terms

beneficially owned regulatory

"Item 4. | Ownership (a) | Amount beneficially owned: OrbiMed Advisors LLC: 884,230"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"OrbiMed Advisors LLC: Shared Dispositive Power 884,230.00"

Schedule 13G/A regulatory

"CONTENT METADATA: "form_type": "SCHEDULE 13G/A""

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

management committee corporate

"the Reporting Persons hold...exercise investment and voting power through a management committee comprised of Carl L. Gordon..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does OrbiMed Advisors hold in Forte Biosciences (FBRX)?

OrbiMed Advisors beneficially owns 884,230 shares, representing 4.3% of common stock as reported in the Schedule 13G/A. The filing states OrbiMed Advisors has shared voting and shared dispositive power over these shares.

How many shares does OrbiMed Capital report owning in FBRX?

OrbiMed Capital reports beneficial ownership of 312,725 shares, equal to 1.5% of the class. The filing shows OrbiMed Capital holds sole voting and sole dispositive power over these shares.

What is the combined ownership percentage reported by the OrbiMed entities in FBRX?

The reporting persons state an aggregate holding of 5.8% of Forte Biosciences common stock on behalf of other persons. This aggregate combines the two entities' disclosed holdings.

Who exercises voting and investment power for the reported shares?

A management committee composed of Carl L. Gordon, Sven H. Borho, and W. Carter Neild is disclosed as exercising investment and voting power. Each committee member disclaims beneficial ownership of the shares.

When were these holdings certified on the Schedule 13G/A?

The signature block shows the filing was signed by Carl L. Gordon as Member on 05/15/2026. That date appears adjacent to both signatures in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:34 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Forte Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

34962G208

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

ORBIMED ADVISORS LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 884,230.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 884,230.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

884,230.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

ORBIMED CAPITAL LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 312,725.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 312,725.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

312,725.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Forte Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 3060 Pegasus Park Dr., Building 6, Dallas, Texas 75247
Item 2.
(a)	Name of person filing: OrbiMed Advisors LLC OrbiMed Capital LLC
(b)	Address or principal business office or, if none, residence: 601 Lexington Avenue, 54th Floor New York, NY 10022
(c)	Citizenship: Please refer to Item 4 on each cover sheet for each filing person.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 34962G208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: OrbiMed Advisors LLC: 884,230 OrbiMed Capital LLC: 312,725
(b)	Percent of class: OrbiMed Advisors LLC: 4.3% OrbiMed Capital LLC: 1.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: OrbiMed Advisors LLC: 0 OrbiMed Capital LLC: 312,725
	(ii) Shared power to vote or to direct the vote: OrbiMed Advisors LLC: 884,230 OrbiMed Capital LLC: 0
	(iii) Sole power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 0 OrbiMed Capital LLC: 312,725
	(iv) Shared power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 884,230 OrbiMed Capital LLC: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Persons hold 5.8% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ORBIMED ADVISORS LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	05/15/2026

ORBIMED CAPITAL LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	05/15/2026